Clinical Trials Directory
We are doing this study to test a new intervention that is designed to help adolescents and young adults who have signs and symptoms of an eating disorder. This study is funded by a grant from the National Institute of Mental Health.
We are doing this study to understand more about biomarkers (a part of your body) and how they can be used to better diagnose infection. To learn more, please contact us at DukeMESSIStudy@Duke.edu or at 919-452-1605. Estamos haciendo este estudio para entender más sobre biomarcadores (que son parte de su cuerpo) y cómo pueden ser usados estos para diagnosticar infecciones de una mejor manera. Para mayor información, por favor contáctenos al correo DukeMESSIStudy@Duke.edu o al número 919-452-1605.
We are doing this study to learn more about the cause of cardiac (heart) disease or sudden unexplained death, which is something that can run in families. Some conditions that we are looking at are:
- Cardiomyopathies (a disease of the heart muscle that makes it harder for your heart to pump blood to the rest of your body) like hypertrophic cardiomyopathy, dilated cardiomyopathy, or arrhythmogenic right ventricular cardiomyopathy
- Arrhythmia syndromes (a problem with the rate or rhythm of the heartbeat, either too slow or too fast) like long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, or short QT syndrome
- Sudden cardiac arrest or unexplained sudden death (heart stops suddenly), including sudden infant death syndrome (SIDS)
We are doing this study to learn from patients' experiences about managing gastroesophageal reflux (GERD) and other risks related to lung transplantation.
We are doing this study to find out if giving heated chemotherapy into the belly, a procedure known as heated intraperitoneal chemotherapy (HIPEC), can improve treatment results for patients with ovarian cancer.
We are doing this study to find out if an experimental drug combination of mirvetuximab (MIRV) plus bevacizumab (BEV) is more effective at managing platinum-sensitive ovarian and fallopian tube cancers in a maintenance setting than bevacizumab on its own.
We are doing this study to find out if a drug called selinexor (the study drug) is a safe and effective option for maintenance therapy for patients with TP53 wild-type endometrial cancer who had a positive response to treatment with chemotherapy.
We are doing this study to find out if an experimental drug called MK-2870 (the study drug) is an option for patients with endometrial cancer. We want to know how well it works compared to standard chemotherapy.